Physician profile
Jonathan E Buzzell
NPI 1215084199
$32,640.29
in general payments reported to CMS, 2019-2025
14 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,278 · 2020: $7,859 · 2021: $6,935 · 2022: $3,524 · 2024: $7,878 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,720 · Travel and Lodging: $1,664 · Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,720.00 |
| Travel and Lodging | $1,664.39 |
| Food and Beverage | $659.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Products, INC. | $25,427.75 | 2019-2024 | Biolox Delta, Inhance |
| Depuy Synthes Sales INC. | $2,986.98 | 2019-2021 | |
| Conetic Solutions, INC. | $1,915.05 | 2022 | |
| Arthrex, INC. | $1,620.12 | 2022-2024 | |
| Stryker Corporation | $531.02 | 2024-2025 | Aequalis Ascend Flex, Aequalis Perform Reversed, Aequalis Perform |
| Ethicon US, LLC | $32.46 | 2022 | |
| Seqirus USA INC | $29.74 | 2021-2022 | |
| Smith+Nephew, INC. | $20.61 | 2020 | |
| Fx Shoulder Solutions, INC | $14.71 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.87 | 2021 | |
| Abbvie INC. | $12.74 | 2022 | |
| Amgen INC. | $12.53 | 2020 | |
| Novo Nordisk INC | $11.98 | 2020 | |
| Lilly USA, LLC | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Buzzell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.